Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist

被引：0
|
作者：
Garnick, Marc B. [1 ]
Hafron, Jason [2 ]
Crawford, E. David [3 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Michigan Inst Urol, Troy, MI USA
[3] Univ Calif San Diego, Koman Family Outpatient Pavil, San Diego, CA 92093 USA
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 03期
关键词：
D O I：
10.1097/JU.0000000000003831
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Crawford, E. David
    Hafron, Jason M.
    Debruyne, Frans
    Wallis, Christopher
    Chang, Steven
    Garnick, Marc B.
    JOURNAL OF UROLOGY, 2024, 211 (01): : 63 - 70
  • [2] Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist
    Stira, Jordi
    Gravina, Carmen
    Lombardo, Riccardo
    De Nunzio, Cosimo
    JOURNAL OF UROLOGY, 2024, 211 (03):
  • [3] Agonists of luteinizing hormone-releasing hormone in prostate cancer
    Rick, Ferenc G.
    Block, Norman L.
    Schally, Andrew V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (16) : 2237 - 2247
  • [4] Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists - In reply
    Meston, CM
    Frohlich, PF
    ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (05) : 470 - 470
  • [5] Gonadotropin-releasing hormone agonists in the treatment of prostate cancer
    Labrie, F
    Bélanger, A
    Luu-The, V
    Labrie, C
    Simard, J
    Cusan, L
    Gomez, J
    Candas, B
    ENDOCRINE REVIEWS, 2005, 26 (03) : 361 - 379
  • [6] The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
    Tomera, K
    Gleason, D
    Gittelman, M
    Moseley, W
    Zinner, N
    Murdoch, M
    Menon, M
    Campion, M
    Garnick, MB
    JOURNAL OF UROLOGY, 2001, 165 (05): : 1585 - 1589
  • [7] Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
    Clinton, Timothy N.
    Woldu, Solomon L.
    Raj, Ganesh V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (08) : 825 - 832
  • [8] Luteinizing hormone-releasing hormone antagonists in prostate cancer
    Stricker, HJ
    UROLOGY, 2001, 58 (2A) : 24 - 27
  • [9] Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol
    Griesinger, G
    Dawson, A
    Schultze-Mosgau, A
    Finas, D
    Diedrich, K
    Felberbaum, R
    FERTILITY AND STERILITY, 2006, 85 (03) : 791 - 793
  • [10] Gonadotropin-Releasing Hormone Agonists for Endometriosis Reply
    Olive, David L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (26): : 2844 - 2845
12345